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Abstract
 
The development of CD1d-dependent natural killer T (NKT) cells is poorly understood. We
have used both CD1d/
 
 
 
-galactosylceramide (CD1d/
 
 
 
GC) tetramers and anti-NK1.1 to inves-
tigate NKT cell development in vitro and in vivo. Confirming the thymus-dependence of
these cells, we show that CD1d/
 
 
 
GC tetramer-binding NKT cells, including NK1.1
 
 
 
 
 
and
NK1.1
 
 
 
 subsets, develop in fetal thymus organ culture (FTOC) and are completely absent in
nude mice. Ontogenically, CD1d/
 
 
 
GC tetramer-binding NKT cells first appear in the thy-
mus, at day 5 after birth, as CD4
 
 
 
CD8
 
 
 
NK1.1
 
 
 
cells. NK1.1
 
 
 
 NKT cells, including CD4
 
 
 
and CD4
 
 
 
CD8
 
 
 
 subsets, appeared at days 7–8 but remained a minor subset until at least 3 wk
of age. Using intrathymic transfer experiments, CD4
 
 
 
NK1.1
 
 
 
 NKT cells gave rise to NK1.1
 
 
 
NKT cells (including CD4
 
 
 
 and CD4
 
 
 
 subsets), but not vice-versa. This maturation step was
not required for NKT cells to migrate to other tissues, as NK1.1
 
 
 
 NKT cells were detected in
liver and spleen as early as day 8 after birth, and the majority of NKT cells among recent thy-
mic emigrants (RTE) were NK1.1
 
 
 
. Further elucidation of this NKT cell developmental path-
way should prove to be invaluable for studying the mechanisms that regulate the development
of these cells.
Key words: T lymphocyte • fetal thymus organ culture • cytokines • T cell development • 
natural killer T cell
 
Introduction
 
CD1d-dependent NKT cells are a distinct lineage of T cells
with unique characteristics (for reviews, see references 1
and 2). These cells include CD4
 
 
 
 and CD4
 
 
 
CD8
 
 
 
 dou-
ble-negative (DN)
 
*
 
 subsets and express a heavily biased
TCR repertoire, with the majority expressing an invariant
V
 
 
 
14J
 
 
 
281 TCR-
 
 
 
 chain and either V
 
 
 
8.2, V
 
 
 
2, or V
 
 
 
7
TCR-
 
 
 
 chains (3–7). NKT cells are potent cytokine pro-
ducers and play a key role as immunoregulatory cells. Per-
haps the best example is in the NOD mouse model for
type-1 diabetes, in which a NKT cell deficiency is directly
related to diabetes susceptibility (8–10). NKT cells have
also been implicated in immunosuppression associated with
anterior chamber–associated immune deviation (11–13),
graft-versus-host disease (14), and allograft tolerance (15).
They can also regulate antitumor responses, sometimes in-
hibiting (16) and sometimes promoting tumor rejection
(17). Thus, abnormalities in NKT cell development that
can alter the numbers of these cells may have a significant
impact on immune responses in a range of diseases.
Although NKT cells are present in the thymus, the de-
velopmental origin of these cells is controversial. Some in-
vestigators have argued that NKT cells are present in thy-
mus-deficient nude mice or in bone marrow–repopulated,
thymectomized adult mice (18–21; for a review, see refer-
ence 1). However, several studies support a thymus-depen-
dent origin for these cells, as they are significantly reduced
in neonatally thymectomized mice (22), CD4
 
 
 
NK1.1
 
 
 
cells are clearly absent from livers of nude mice (23), and
canonical TCR V
 
 
 
14J
 
 
 
281 rearrangements are not de-
tected in irradiated, thymectomized, and fetal liver–repop-
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ulated adult mice (24). Some of these conflicting results
may be due to the fact that some NK1.1 expressing T cells
exist that are quite distinct from “classical”, CD1d-depen-
dent, NKT cells (2, 25, 26). These cells, sometimes referred
to as type-II NKT cells, are CD1d independent, mostly
CD4
 
 
 
, have diverse TCRs, may be thymus independent,
and their functional significance is unknown. Given that
conventional T cells can upregulate NK1.1 after activation
(27, 28), CD1d-independent NK1.1
 
 
 
 T cells may be a
highly diverse population including MHC-I– and MHC-
II–restricted cells, and possibly represent an activation state
rather than a unique lineage. In this paper, the term “NKT
cells” refers only to the CD1d-dependent population.
CD1d/
 
 
 
-GalCer tetrameric complexes, which bind stably
and selectively to V
 
 
 
14J
 
 
 
281-expressing NKT cells, cur-
rently represent the best reagent for identifying CD1d-
dependent NKT cells (29, 30). Although 
 
 
 
-GalCer is a
nonmammalian glycolipid, originally derived from marine
sponges, NKT cells specifically interact with this molecule,
in a strictly CD1d-dependent manner (31, 32). In this pa-
per, CD1d/
 
 
 
GC tetramers have been used to identify
NKT cells, thus avoiding complications due to promiscu-
ous expression of, or lack of, NK1.1.
The intrathymic development of NKT cells depends on
CD1d expression by CD4
 
 
 
CD8
 
 
 
 double positive (DP)
thymocytes rather than thymic epithelial cells (23, 33–37).
Although little information exists for a developmental
pathway for NKT cells, two models have been proposed
for their development (1). One model suggests that the
generation of NKT cells results from programmed gene
rearrangements that yield the invariant TCR-
 
 
 
 chain; the
other model suggests that this TCR is the result of random
gene rearrangements and that NKT cells are selected from
the mainstream T cell lineage at the DP stage of thy-
mocyte development, as this is where TCR-
 
 
 
 gene rear-
rangement, expression, and auditioning for selection oc-
curs. In strong support of the latter model, the invariant
TCR-
 
 
 
 chain often carries N nucleotide additions that
generate the canonical amino acid sequence; moreover,
the homologous chromosome often carries random TCR-
 
 
 
gene rearrangements. (5, 38). Several studies support the
concept that NKT cells are a developmentally distinct lin-
eage. In contrast to conventional T cells, NKT cell devel-
opment appears to require an interaction with membrane
lymphotoxin expressing cells (39, 40). NKT cell develop-
ment is also absolutely dependent on pre-T
 
 
 
 signaling (41)
and at least partly dependent on GM-CSF signaling (42).
Fyn-deficient mice show a selective defect in the develop-
ment of CD1d-dependent NKT cells, but not of conven-
tional T cells (43, 44). Analysis of NKT cells in common
cytokine receptor 
 
 
 
 chain–deficient mice revealed at
least two stages in NKT cell development (45). Such
mice generate thymocytes expressing normal amounts of
V
 
 
 
14J
 
 
 
281 mRNA and develop IL-4–producing CD8
 
 
 
cells, suggesting the presence of NKT cells, yet these cells
fail to express the NK receptors NK1.1 or Ly49 and are not
exported to the periphery. Thymic stromal cell–derived
cytokines IL-15 and IL-7 are required for development of
normal numbers and IL-4–producing potential, respec-
tively, of NKT cells (46, 47), and an intact thymic struc-
ture is also important (48).
In this study, we have examined NKT cell development
in the thymus both in in vitro fetal thymus organ cultures
(FTOC) and also during ontogeny in vivo. Using CD1d/
 
 
 
GC tetramers, NK1.1, and CD4 in combination, we have
demonstrated the existence of a developmental pathway
showing that the earliest CD1d-dependent NKT cells are
CD4
 
 
 
CD8
 
 
 
NK1.1
 
 
 
. These cells are precursors of NK1.1
 
 
 
NKT cells, including both CD4
 
 
 
 and DN subsets. This
later maturation event is not required for thymic emigra-
tion, as immature NK1.1
 
 
 
 cells are also present in spleen
and liver of young mice, and these cells are abundant
among recent thymic emigrants (RTE).
 
Materials and Methods
 
Mice.
 
C57BL/6 mice, CD45.1 congenic C57BL/6, BALB/c,
and BALB/c 
 
nu/nu
 
 mice (C57BL/6 
 
nu/nu
 
 mice were not avail-
able in Australia) were obtained from either the Animal Re-
sources Centre (Canning Vale, WA) or Monash University Cen-
tral Animal House (Clayton, Victoria, Australia) and housed for 1
to 2 wk in micro-isolators in the Monash University Medical
School Animal House (Prahran, Victoria, Australia). Embryonic
thymuses for FTOC were derived from plug-timed pregnant
mice where time of finding a plug was taken to be day 0. Perina-
tal mice were timed such that the day of birth was referred to as
day 1. All mouse experiments were approved by the Monash
University Animal Ethics Committee – Alfred Hospital branch.
 
FTOC.
 
Fetal thymus lobes were obtained at embryonic day
14 (E14) from plug-timed pregnant C57BL/6 mice as described
previously (49). FTOC was performed in culture media consist-
ing of RPMI-1640 (Life Technologies), 10% FCS (Common-
wealth Serum Laboratories [CSL], Melbourne, Victoria, Austra-
lia), 2 mM GlutaMAX, 50 
 
 
 
M 2-ME, 100 IU/ml penicillin, and
100 
 
 
 
g/ml streptomycin, 15 mM HEPES buffer (Life Technolo-
gies), and 1 mM sodium pyruvate (Life Technologies). Lobes
were cultured in groups of 4–6 per well of a 6-well plate for up
to 18 d with a media change every 6 d of culture. At the end of
culture, thymocytes were harvested from lobes, counted, and an-
alyzed by flow cytometry.
 
Cell Suspensions.
 
Cell suspensions of thymus and spleen were
prepared as described previously (26). Hepatic leukocytes were
isolated by cutting individual livers into small pieces and gently
pressing through a 200-gauge wire mesh. The cells were washed
twice in ice-cold PBS with 2% FCS and 0.02% Azide and spun
through 33.8% Percoll (Amersham Pharmacia Biotech) for 12
min at 693 
 
g
 
. Recovered leukocytes were washed and treated
with red cell removal buffer (Sigma-Aldrich). Hepatic leukocytes
from mice at days 5 and 8 were isolated by gently grinding the
organ between frosted glass slides and staining without further
enrichment, using a lymphocyte gate based on forward versus
side light scatter for flow cytometry.
 
Flow Cytometry.
 
The following mAbs were used in multi-
parameter flow cytometric analysis: anti-: 
 
  
 
TCR-allophycocya-
nin (APC) (clone H57–597), CD4-FITC or CD4-PerCP (clone
RM4–5), CD8-biotin, CD8-PerCP or CD8-FITC (clone 53–
6.7), NK1.1-PE or biotin (clone PK136, mouse IgG2a),
CD45.2-FITC (clone 104; all purchased from BD PharMingen).
Biotinylated mAb were detected with streptavidin-Alexa Fluor™ 
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488 (Molecular Probes), streptavidin-PerCP, or streptavidin APC
(BD PharMingen). Fc-receptor block (anti-CD16/CD32, clone
2.4G2 culture supernatant) was always added to staining cocktails.
PE-labeled, 
 
 
 
-GalCer–loaded or –unloaded (control) mCD1d
tetramers were produced in-house at La Jolla Institute for Allergy
and Immunology (30). One fluorescence channel was often not
used for specific staining but instead used for the exclusion of au-
tofluorescent cells. Three and four-color analysis, as well as multi-
color sorting, was performed using a FACSCalibur™ or FAC-
Star
 
PLUS™
 
 (Becton Dickinson). CELLQuest™ software (Becton
Dickinson) was used for analysis.
 
Isolation of NKT Cell Subsets for In Vitro Cytokine Assays.
 
Thymic NKT cells were enriched by depletion of CD24 (HSA)
 
 
 
and CD8
 
 
 
 thymocytes with rat anti–mouse CD24 (clone J11D)
and rat anti–mouse CD8 (clone 3.155), respectively, followed by
rabbit complement (C-six Diagnostics Inc.). NK1.1
 
 
 
 or NK1.1
 
 
 
CD1d/
 
 
 
GC tetramer
 
 
 
 thymocytes were sorted to greater than
92% purity and stimulated by culturing in anti-CD3–coated mi-
crotitre plates (clone 145–2C11; BD PharMingen). Cells were
cultured at a density of 10
 
5
 
 cells in 100 
 
 
 
l tissue culture medium.
Supernatants were harvested at 24 and 48 h, and IL-4 and IFN-
 
 
 
levels were detected by sandwich ELISA as described previously
(26). Generally the limit of detection for IL-4 was 2 U/ml, and
IFN-
 
 
 
 0.1 ng/ml. Quantitative differences between samples were
compared with the Mann Whitney U (rank sum) test.
 
In Vivo Labeling of Thymocytes with FITC.
 
The technique for
in vivo thymocyte labeling with FITC has been described previ-
ously in detail (50). Briefly, 6-wk-old mice were anesthetized and
intrathymically injected with 10 
 
 
 
l of FITC (Sigma-Aldrich; 1
mg/ml in PBS) per lobe. The mice were subsequently injected
subcutaneously with 0.03 mg of Buprenorphine analgesic (Reck-
itt and Coleman). Mice were killed 36 h later and their organs re-
moved for flow cytometric analysis of RTE.
 
Intrathymic Injection of Cells.
 
NKT cell subsets derived from
thymuses of 4-wk-old C57BL/6 mice were separated into
NK1.1
 
 
 
 and NK1.1
 
 
 
 fractions by FACS
 
®
 
 sorting, and intrathy-
mically injected into CD45.1 congenic C57BL/6 recipient mice.
Intrathymic injections were performed in a similar fashion to that
described for FITC injection, except cells were injected into one
lobe of the thymus in a volume of 10 
 
 
 
l of PBS and mice were
killed 7 or 14 d later. For these experiments, 2 
 
 
 
 10
 
5
 
NK1.1
 
 
 
CD4
 
 
 
HSA
 
 
 
/low
 
 cells, or 2 
 
 
 
 10
 
6
 
 NK1.1
 
 
 
CD4
 
 
 
HSA
 
 
 
/low
 
cells were injected. The latter population was injected in larger
numbers, since upon restaining, it included more than just
NK1.1
 
 
 
CD1d/
 
 
 
GC tetramer
 
 
 
 NKT cells, which were typically
 
 
 
10% of the injected cells. This approach was used in preference
to sorting directly, using the tetramer, for CD4 CD1d/ GC
tetramer  NK1.1  cells, as the tetramer reagent would probably
artificially stimulate the NKT cells through TCR cross-linking.
To control for the possibility that other CD4 HSA /low cells
were giving rise to the NKT cells subsequently detected in the
recipient mice, a separate group of mice were injected with
CD4 HSA /low cells that had been depleted of CD1d/ GC
tetramer  cells. Sorted cell purities were always  98% for the
NK1.1  fraction and 94% for the NK1.1  fraction.
Results
CD1d-dependent NKT Cell Development Is Thymus Depen-
dent. The thymus dependence of NKT cells is an ongo-
ing area of debate. Although NK1.1 expressing T cells
have been identified in FTOC (4), we sought to revisit
this technique using CD1d/ GC tetramer, which would
permit identification of NKT cells without relying on
NK1.1 expression, thus including NK1.1  CD1d-depen-
dent NKT cells (2, 29, 30). As shown in Fig. 1, and in
support of the earlier study by Bendelac et al. (4), CD1d/
 GC tetramer-binding NKT cells develop in FTOC, al-
though they did not appear until between 11 and 13 d of
culture, whereas conventional   TCRhigh cells were
present as early as 6 d of FTOC (not shown). The major-
ity of these NKT cells were CD8 , and unexpectedly,
NK1.1  (Fig. 1). In contrast, most NKT cells in adult
thymus were NK1.1 , with a minor subset of CD4 
NK1.1  cells (Fig. 1), as has been reported previously
(29, 30). CD1d/ GC tetramer-reactive NKT cells accu-
mulated with time in these cultures from day 12 to day
18 (Fig. 1 B). Parallel analysis of NK1.1   TCR  cells
in these cultures gave significantly different results. These
cells appeared at a similar rate and time, however, the
majority did not stain with CD1d/ GC tetramer (Fig. 1
B) and although some NK1.1  CD1d/ GC tetramer 
cells were CD4 CD8  and CD4 CD8 , between 10–
30% were CD4 CD8  (data not shown), a phenotype
that was never seen for CD1d/ GC tetramer  cells.
Taken together, these findings support and significantly
expand on results from the previous study (4), showing
that both NK1.1  and NK1.1  NKT cells can develop
in FTOC, and also reveal that NK1.1 in isolation is not
an ideal marker for studying NKT cell development in
FTOC. Nonetheless, these FTOC experiments con-
firmed that NKT cells can develop in the thymus in the
absence of extrathymic factors, but did not exclude an al-
ternative, extrathymic pathway for the development of
these cells.
Several studies have investigated whether NKT cells
exist in athymic nude mice, with highly ambiguous re-
sults (for a review, see reference 1). Therefore, we ex-
amined spleen and liver lymphocytes of nude mice for
the presence of CD1d/ GC tetramer-binding NKT
cells (Fig. 2). These experiments, performed using
young (13-d-old), and aged (11-wk-old) mice, revealed
a complete absence of NKT cells in the absence of a
thymus. Taken together with the FTOC data, this
clearly demonstrates that the thymus is both necessary
and sufficient for the development of CD1d-dependent
NKT cells.
Developmentally Regulated Appearance of NKT Cell Sub-
sets. Given that many NKT cells exhibited an NK1.1 
phenotype in FTOC, it was important to investigate
whether this represented an immature stage in the develop-
ment of these cells. Thus, thymus, spleen, and liver lym-
phocytes were examined for CD1d/ GC tetramer-binding
NKT cells from a range of developmental stages between
day 3 after birth to adult (Figs. 3 and 4; day of birth   day
1). NKT cells were first detected in very low percentages
and numbers in the thymus, but not other tissues, at day 5
and increased steadily from then on (Fig. 3). These cells
were detected in spleen and liver at day 8, and also accu-
mulated at a similar rate to that seen in the thymus. Multi-838 NKT Cell Development
parameter flow cytometric analysis of thymic NKT cells
at day 5 revealed that nearly all of these cells were
CD4 CD8 NK1.1  (Fig. 4 A). NK1.1  cells gradually
emerged in the thymus over the next few days, but re-
mained in the minority until at least day 28. This supports
the concept that NK1.1  NKT cells represent a precursor
stage in the development of NKT cells. Similar populations
of NKT cells appeared in spleen and liver from day 8 on-
Figure 1. CD1d-dependent NKT cell development is thymus dependent. (A) Thymocytes were harvested from FTOC after 11, 13, 15, and 18 d of
culture and stained for multi-parameter flow cytometric analysis. An adult thymus sample is included as a labeling control. The first column shows
CD1d/ GC tetramer   TCR  cells with the percentages indicated. The second column shows CD4 versus NK1.1 expression on NKT cells, gated as
shown in the first column. The third column shows CD4 versus CD8 expression on NKT cells, gated as shown in the first column. (B) The data from all
FTOC experiments were graphed and means   standard error plotted as shown. In some cases where the error was very low, no bars are visible. Results
are from 1–5 different experiments with at least four separate cultures per experiment. Tetramer, CD1d/ GC tetramer.
Figure 2. NKT cells are ab-
sent from spleen and liver of
nude mice. Spleens and livers
were harvested from BALB/c
nude (nu/nu) mice at day 13 after
birth and at 11 wk of age. Cells
were counted and labeled for
flow cytometric analysis. Day 13
heterozygous ( /nu) littermates
and 11-wk-old wild-type ( / )
BALB/c spleen and liver cells
were examined in parallel as a
control to show that labeling for
CD1d/ GC tetramer    TCR 
cells was as expected. Dotplots
are representative of five day 13
and three 11-wk-old BALB/c
nude (nu/nu) mice. Three nude
mice were also screened at 7
wk of age with similar results
(not shown).839 Pellicci et al.
wards (Fig. 4, B and C), including a majority of NK1.1 
NKT cells. This suggested that less mature NK1.1  NKT
cells are able to leave the thymus before acquisition of
NK1.1 expression, and may subsequently acquire a more
mature phenotype in the peripheral organs. Regardless of
the stage of development, a very minor subset of cells
within the NKT cell gate in the thymus appeared to ex-
press both CD4 and CD8 (Fig. 4 A). Similar cells have
been previously observed (30) and the possibility has been
raised that they represent an early precursor stage in the
NKT cell lineage (51). However, we did not detect a stage
during NKT cell ontogeny at which these cells appeared to
be significantly more abundant, and careful analysis of these
cells showed that they appeared to be larger than other
NKT cells based on forward light scatter (data not shown),
suggesting that they might be doublets. Furthermore, when
these cells were sorted from adult thymus and vigorously
resuspended before rerunning through the flow cytometer,
nearly all of these appeared to be derived from doublets
that had formed between DP thymocytes and CD4 CD8 
or DN NKT cells (data not shown).
Most NKT Cells Leave the Thymus as NK1.1  Cells.
Recent thymic emigrants were identified by intrathymic
injection of FITC dye, and RTE were examined 36 h
later for CD1d/ GC tetramer and NK1.1 staining (Fig.
5). NKT cells were clearly identifiable as CD1d/ GC
tetramer  cells within the RTE population of both spleen
and liver. Furthermore, the majority of these cells (FITC 
NKT cells) were NK1.1 , despite the fact that resident
(FITC ) NKT cells in these tissues were mostly NK1.1 .
Similar results were obtained when NKT RTE from blood
were examined (data not shown).
Thymic NK1.1  NKT Cells Are Progenitors of NK1.1 
NKT Cells. Analysis of NKT cells through ontogeny
(Fig. 4) strongly suggested that CD4 NK1.1  NKT cells
represent an intermediate stage in their development. To
directly test this, we separated CD4  NKT cells into
NK1.1  and NK1.1  subsets and adoptively transferred
these into CD45.1 congenic recipient mice by intrathymic
injection (Fig. 6). It was important to avoid using the
CD1d/ GC tetramer to sort these cells, which might lead
to TCR stimulation and artificially lead to their activation.
Therefore, donor cells were sorted as CD4 HSA /low
NK1.1  or NK1.1  fractions. Donor-derived NKT cells
were clearly identifiable in thymuses screened at 1 wk after
transfer (Fig. 6). Whereas nearly all NK1.1 CD4  NKT
cells remained NK1.1 CD4 , the majority of the NK1.1 
NKT cell fraction yielded NK1.1  NKT cells within 1 wk,
including CD4  and CD4  subsets. Very similar results
were observed two weeks after transfer (data not shown).
Importantly, when CD4 HSA /low cells were depleted of
CD1d/ GC tetramer-binding cells before transfer, NKT
cells were not detected in recipient mice, indicating that
NK1.1  NKT cells, and not other CD4 HSA /low cells,
were responsible for the emergence of donor-derived NKT
cell populations in these experiments. These results
strongly suggest that thymic NK1.1  NKT cells represent a
precursor stage in the development of this lineage.
NK1.1  NKT Cells Produce High Levels of IL-4.
NK1.1  and NK1.1  subsets of NKT cells were separated
by FACS® sorting and examined for cytokine production
in the presence of plate-bound anti-CD3 antibodies (Table
I). NK1.1  NKT cells made high levels of both IL-4 and
IFN- , as expected from previous studies (26). Remark-
ably, at both 24 and 48 h, NK1.1  NKT cells produced
higher levels of IL-4, and lower levels of IFN- , than their
NK1.1  counterparts. Thus, although NK1.1  NKT cells
seem to be developmentally less mature, the capacity to
produce high levels of cytokines, particularly IL-4, appears
to be an early event in the development of this lineage.
Discussion
Despite the identification of NKT cells over 14 years
ago, the developmental origin and pathway has remained
an unresolved and controversial area (for reviews, see refer-
ences 1 and 2). Whereas several studies have provided evi-
dence in support of an extrathymic origin for NKT cells
(for example, references 18–20 and 52–54), others pro-
vided evidence to the contrary (4, 22–24, 55–57). Some of
this controversy may be explained by the absence of reli-
able and specific reagents to identify NKT cells. Even
NK1.1, which has traditionally been used for the identifi-
cation of NKT cells in C57BL/6 mice, is not ideal for two
reasons: not all CD1d-dependent NKT cells express NK1.1
(even in C57BL/6 mice [29, 30, 58]), and not all NK1.1-
Figure 3. Ontogeny of NKT cells. Thymuses, spleens, and livers were
removed from C57BL/6 mice at various ages and harvested cells counted
and labeled for flow cytometric analysis. The first column shows mean
percentages of CD1d/ GC tetramer    TCR  NKT cells, and the sec-
ond column shows mean numbers of these cells. The error bars represent
standard error of the mean. In some cases where the error was very low,
no bars are visible. Results are from 4–12 mice per time point.840 NKT Cell Development
expressing   TCR  cells exhibit the characteristics nor-
mally associated with NKT cells (25, 26, 29, 30; for a re-
view, see reference 2). CD1d/ GC tetramers represent the
first reagent that clearly and specifically defines CD1d-depen-
dent NKT cells (29, 30). A potential limitation with
this reagent may lie in the existence of CD1d-dependent
NKT cells that do not recognize  -GalCer, although it ap-
pears to encompass the majority of invariant NKT cells
Figure 4. Phenotype of NKT cells during development. C57BL/6 mice were killed at various ages and (A) thymus, (B) spleen, and (C) liver harvested,
cells counted, and labeled for flow cytometric analysis. The first column shows CD1d/ GC tetramer   TCR  cells with the percentages indicated.
The second column shows CD4 versus NK1.1 expression on NKT cells, gated as shown in the first column. The third column shows CD4 versus CD8
expression on NKT cells, gated as shown in the first column. As a staining control, CD4 versus CD8 labeling on total thymocytes is shown in the inset
dotplot in the bottom row (Adult) of the third column. Dotplots are representative of 4–12 mice per time point. ND, not determined.
Figure 5. Preferential t hymic
emigration of NK1.1  NKT cells.
RTE were tracked following in-
trathymic injection of FITC dye.
36 h after injection, lymphocytes
were harvested from thymus,
spleen, and liver, counted, and
stained for flow cytometric analysis.
FITC  cells were gated above the
line shown in the first column. The
second column shows that FITC 
(FL-1 ) events in the spleen and
liver do not occur when FITC has
not been injected intrathymically.
The third column shows CD1d/
 GC tetramer     TCR  NKT
cells within the RTE population.
The third and fourth columns
show NK1.1 expression on NKT
cells within the FITC  RTE and
FITC  resident cell populations in
each tissue. Dotplots are represen-
tative of four separate mice from
one experiment.841 Pellicci et al.
(29) and is therefore a great improvement over previous
approaches. There is currently no reagent available that can
reliably detect all CD1d-dependent NKT cells, regardless
of their specificity for  -GalCer. Using CD1d/ GC tetra-
mers, we have verified, and expanded upon, earlier studies
(4, 59), showing that CD1d/ -GalCer-dependent NKT
cells (including both NK1.1  and NK1.1  subsets) can de-
velop in the thymus in isolation (FTOC), and are absent in
the spleen and liver of nude mice. This data firmly supports
the contention that the thymus is both necessary and suffi-
cient for the development of these cells.
This study has also revealed that NKT cells are clearly
identifiable before their acquisition of the NK1.1 marker,
and strongly suggests that CD1d-dependent NK1.1  NKT
cells in the thymus represent a precursor stage in the devel-
opment of this lineage. Whereas the thymus appears to be
important for NKT cells to reach the intermediate NK1.1 
stage, further maturation appears to be able to occur
outside of the thymus, and indeed, the majority of
NKT cells leaving the thymus are NK1.1 . Our data indi-
cate that thymic CD4 NK1.1  NKT cells give rise to
CD4 NK1.1  and CD4 NK1.1  subsets. These may each
develop directly from CD4 NK1.1  population, as most
CD4 NK1.1  NKT cells retained that phenotype follow-
ing transfer. This pathway contrasts an earlier pathway pro-
posed by MacDonald (51), based on NK1.1  NKT cell on-
togeny, suggesting that DN NKT cells develop before
CD4  NKT cells. Indeed, our data in Fig. 4 of this paper
would support the argument that NK1.1  DN are more
abundant than NK1.1 CD4  NKT cells early in thymic
ontogeny. However, these data need to be reinterpreted in
light of our results; although DN NKT cells appear to pre-
dominate among the more mature NK1.1  fraction (sug-
gesting that they mature faster than the CD4 NK1.1  frac-
tion), the earliest detectable NKT cells are CD4  and
NK1.1 . In support of our data demonstrating the exist-
ence of an NK1.1  NKT cell precursor stage, an earlier
study by Lantz et al. (45) demonstrated that NKT cells ap-
peared to partly develop in common  -chain–deficient
mouse thymus, based on normal frequency of V 14J 281
expressing, IL-4–producing cells, yet these cells failed to
acquire NK1.1 and Ly49 expression. However, these mice
also lacked NKT cells in the periphery, leading the authors
to suggest that full maturation to the NK1.1  stage was re-
quired for emigration of NKT cells. Although our data dif-
fers on this point, an alternate view that could satisfy both
studies is that the common  -chain is required for the emi-
gration of less mature NK1.1  NKT cells, as well as for
their maturation within the thymus. The ability of the ear-
lier NK1.1  NKT cells to produce very high levels of IL-4
and moderate IFN-  might suggest that these cells are
functionally competent and may participate in immune re-
sponses, as these cells also exist in the periphery (29, 30,
Figure 6. NK1.1  NKT cells are precursors of NK1.1  NKT cells.
NK1.1 CD4 HSAlow and NK1.1 CD4 HSAlow populations from 4-wk-
old C57BL/6 (CD45.2 ) thymuses were purified by FACS® sorting
and intrathymically injected into CD45.1 congenic C57BL/6 recipient
mice. 1 wk later, recipient thymuses were harvested and donor-derived
cells identified based on CD45.2 expression. A gate was placed around
CD1d/ GC tetramer  CD45.2  NKT cells which were examined for
CD4 versus NK1.1 expression. The percentage of acquisition-gated
CD45.2  cells that were CD1d/ GC tetramer  is shown. These results
are representative of three experiments with 1–3 recipient mice per group
per experiment. Controls included transfer of CD4 HSA /low cells that
had previously been depleted of CD1d/ GC tetramer  cells (third row)
and PBS-injected thymuses (last row). Tetramer, CD1d/ GC tetramer.
Table I. Cytokine Production by NK1.1  and NK1.1  CD1d/
 -GC Tetramer  Thymocytes
IL-4 IFN- 
NK cell
subset Day 1 Day 2 Day 1 Day 2
U/ml/105 cellsa ng/ml/105 cells
NK1.1  4,400   500b 13,000   1,000 2.2   0.3 15   3
NK1.1  1,160   80c 2,900   200c 16   2c 150   20c
FACS®-sorted NK1.1 /  CD1d/ -GC  thymocytes from 4-wk-old
C57BL/6 mice were stimulated in anti-CD3–coated microtitre plates.
IL-4 and IFN-  were measured by ELISA from supernatants which
were harvested at 24 and at 48 h.
a100 U/ml is equivalent to 1 ng/ml (BD PharMingen IL-4 standard).
bData represents mean   standard error for 15 individual culture repli-
cates for NK1.1  CD1d/ -GC  thymocytes and 10 replicates for
NK1.1  CD1d/ -GC  from three separate experiments.
cP   0.05 compared to NK1.1  subset (Mann-Whitney U rank sum test).842 NKT Cell Development
60), and peripheral NK1.1  NKT cells have also been
shown to have a similar phenotype (58, 61). Alternatively,
this characteristic may be related to the development of this
lineage, possibly related to their exposure to intrathymic
IL-7, a cytokine which potentiates IL-4 production by
NKT cells (46, 58). A trivial explanation for the difference
in IL-4 and IFN-   production by these two subsets of
NKT cells might be related to cross-linking of NK1.1 dur-
ing the purification of the NK1.1  fraction, which may en-
hance IFN-  (62) and in turn suppress IL-4 synthesis. Al-
though our ontogeny and transfer data indicate that
NK1.1  NKT cells give rise to NK1.1  NKT cells, it re-
mains possible that some NK1.1  NKT cells are not pre-
cursors, and may be mature NKT cells, particularly in the
periphery. In line with this possibility, NK1.1  NKT cells
can at least transiently downregulate NK1.1 expression af-
ter TCR-mediated activation (63), although it remains to
be determined whether this happens when NKT cells are
activated in vivo.
While this paper was under review, another study was
published providing evidence that early CD1d-dependent
NKT cells were CD4lowCD8low (64). This clearly contrasts
with our data, and we are unable to easily explain the basis
for this difference. An unusual approach in the other study
was that CD1d/ GC tetramer-binding thymocytes were
preenriched using anti-PE conjugated magnetic beads,
whereas our study involved labeling of whole, unenriched
thymocytes. Another difference is that Gapin et al. did not
appear to include colabeling with anti-  TCR to exclude
CD1d/ GC tetramer-binding non-T cells, as have been
previously reported (29, 30, 60) and as were observed in
our results in this paper (Fig. 4). Finally, we should add
that we first detected tetramer  NKT cells at day 5 after
birth, when nearly all were NK1.1 CD4 CD8 , whereas
the CD4lowCD8low cells reported in the other study (at
days 6 and 9) did not exceed 30%. At no time did we ob-
serve a distinct population of cells with this phenotype.
Taken together, we believe that our data provides a more
reliable phenotype for early CD1d/ GC tetramer-binding
NKT cells.
The precise factors that regulate the developmental steps
in the NKT cell lineage remain to be determined. Expres-
sion of CD1d by DP thymocytes (23, 34) is clearly required
to reach the first NK1.1  stage, as CD1d tetramer-binding
cells were not detected in the thymus of  2m or CD1d-
deficient mice (30). Factors that might be important in the
progression to NK1.1 expression are unknown, but may
involve signaling through the common  -chain (45).
Given that NKT cells seed to the periphery at the imma-
ture NK1.1  stage, these maturation signals may be thymus
independent. Until recently, the stage at which NKT cells
branch away from the mainstream    T cell lineage was
unknown. It was hypothesized to occur at the DP stage, as
this is where TCR-  gene rearrangement begins and thy-
mocytes first start to express surface TCR-   and audition
for intrathymic selection. As NKT cells appear to arise
through randomly generated TCR-  gene rearrangements,
the most likely model is that their uncommitted precursors
receive an instructive signal via CD1d at the DP precursor
stage that diverts developing thymocytes from the main-
stream    T cell lineage as they express cell surface TCR.
The study by Gapin et al. (64), provides direct evidence for
such a pathway, showing that intrathymic adoptive transfer
of DP thymocytes leads to the generation of NKT cells.
Although, as mentioned above, we were unable to detect a
clear population of NKT cells with a DP phenotype at any
stage of ontogeny, it is possible that CD8 down-regulation
occurs before TCR upregulation to levels that are suffi-
ciently high to be detectable by CD1d/ GC tetramer
staining. Apart from the clear necessity for CD1d expres-
sion by DP thymocytes (23, 33–37), the signals that control
this branch-point are poorly defined. Whether CD4 or
CD8 molecules are actually involved in this step is an im-
portant question. NKT cells develop in both CD4 /  and
CD8 /  mice, although NKT cells in CD8 /  mice
showed an altered TCR V  usage (4), whereas forced
(transgenic) expression of CD8 prevents the development
of NKT cells. This suggests that although CD8 might play
a minor role in NKT cell selection, its down-regulation af-
ter selection is vital for their survival.
In summary, we have identified the CD4 NK1.1 
CD1d/ GC tetramer-binding population as a thymus-
dependent precursor stage in NKT cell development.
These cells are able to seed to the periphery before acquisi-
tion of an NK1.1  phenotype, suggesting that subsequent
maturation to the mature NK1.1  subsets may occur both
within and outside of the thymus. This proposed pathway
of NKT cell development should prove to be invaluable
framework for understanding the mechanisms that control
the development of this important lineage of cells.
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